169
Views
0
CrossRef citations to date
0
Altmetric
Letters

Refractory systemic lupus erythematosus with neuropsychiatric manifestations successfully treated with anifrolumab

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 226-228 | Received 01 Nov 2023, Accepted 12 Jan 2024, Published online: 26 Jan 2024
 

Disclosure statement

SH has received speaking fees from AstraZeneca. The other authors declare no conflicts of interest associated with this manuscript.

Patient consent

Written, informed consent was obtained from the four patients by the corresponding author. The signed consent forms are retained by the corresponding author. Patient details were anonymized as much as possible.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.